

by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedules I and II:

Drug	Schedule
Marihuana (7360) .....	I
Tetrahydrocannabinols (7370) .....	I
4-Bromo-2, dimethoxyamphetamine. (7391) .....	5- I
3, Methyleneedioxymethamphetamine. (7405) .....	4- I
Amphetamine (1100) .....	II
Phencyclidine (7471) .....	II
Cocaine (9041) .....	II
Diprenorphine (9058) .....	II
Fentanyl (9801) .....	II

The company plans to import small quantities of the above listed controlled substances for non-clinical, laboratory-based research only.

In reference to drug code 7360 (Marihuana), the company plans to import synthetic cannabinoid agonists. In reference to drug code 7370 (Tetrahydrocannabinols), the company will import a synthetic Delta-9-THC. No other activity for these drug codes are authorized for this registration.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.

Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than January 11, 2010.

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the **Federal Register** on September 23, 1975, (40 FR 43745-46), all applicants for registration to import a basic class of any controlled substances in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21

CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: December 1, 2009.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. E9-29542 Filed 12-10-09; 8:45 am]  
**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Office of Justice Programs

[OJP (NIJ) Docket No. 1510]

### Vehicular Digital Multimedia Evidence Recording System Standard Special Technical Committee

**AGENCY:** National Institute of Justice.

**ACTION:** Notice of request for proposals for certification and testing expertise.

**SUMMARY:** The National Institute of Justice (NIJ) is in the process of developing a new Vehicular Digital Multimedia Evidence Recording System Standard and corresponding certification program requirements. This work is being performed by a Special Technical Committee (STC), comprised of practitioners from the field, researchers, testing experts, certification experts, and representatives from stakeholder organizations. It is anticipated that the STC members will participate in six 2-day meetings over a 9-month time period with the goal of completing development of the standard and certification program requirements. It is anticipated that STC meetings will begin in mid-January 2010. Travel expenses and per diem will be reimbursed for all STC meetings; however, participation time will not be funded.

NIJ is seeking representatives from (1) certification bodies and (2) test laboratories with experience in programs for similar types of electronic equipment. Additional preferred knowledge includes experience with in-car video systems or experience with law enforcement operations. There are up to four positions to be filled on the STC, and NIJ will accept the first 20 submissions for review.

Interested parties are requested to nominate individuals from their organizations and submit no more than two pages describing the nominee's applicable experience, preferred knowledge, and affiliations with standards development organizations. This information shall be submitted to Frances Scott at [frances.scott@usdoj.gov](mailto:frances.scott@usdoj.gov) by December 22, 2009. The submissions will be reviewed, and participants will be notified regarding their acceptance by January 8, 2009.

### FOR FURTHER INFORMATION CONTACT:

Cassandra Robinson by telephone at 202-305-2296 [Note: this is not a toll-free

Drug	Schedule
Tetrahydrocannabinols (7370) .....	I
Dihydromorphine (9145) .....	I
Dihydrocodeine (9120) .....	II
Oxycodone (9143) .....	II
Hydromorphone (9150) .....	II
Hydrocodone (9193) .....	II
Remifentanil (9739) .....	II
Sufentanil (9740) .....	II
Fentanyl (9801) .....	II

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

In reference to drug code 7370 the company plans to bulk manufacture a synthetic Tetrahydrocannabinol. No other activity for this drug code is authorized for this registration.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than February 9, 2010.

Dated: December 1, 2009.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. E9-29527 Filed 12-10-09; 8:45 am]  
**BILLING CODE 4410-09-P**